X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7886) 7886
Publication (849) 849
Book Review (830) 830
Book Chapter (27) 27
Conference Proceeding (12) 12
Book / eBook (8) 8
Dissertation (7) 7
Magazine Article (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7583) 7583
humans (5816) 5816
aryl hydrocarbon hydroxylases - genetics (4246) 4246
male (3468) 3468
female (3085) 3085
animals (2867) 2867
pharmacology & pharmacy (2544) 2544
aryl hydrocarbon hydroxylases - metabolism (2100) 2100
genotype (2001) 2001
cytochrome p-450 enzyme system - genetics (1941) 1941
aryl hydrocarbon hydroxylases (1729) 1729
adult (1680) 1680
cytochrome p-450 cyp2c19 (1599) 1599
middle aged (1595) 1595
cytochrome p-450 cyp2c9 (1394) 1394
polymorphism, genetic (1338) 1338
mixed function oxygenases - genetics (1301) 1301
cytochrome p-450 enzyme system - metabolism (1299) 1299
metabolism (1293) 1293
cytochrome p-450 (1242) 1242
mice (1171) 1171
aged (1077) 1077
rats (1067) 1067
pharmacogenetics (1023) 1023
biochemistry & molecular biology (981) 981
cytochrome p-450 cyp1b1 (946) 946
toxicology (926) 926
alleles (795) 795
cytochrome p450 (780) 780
expression (777) 777
polymorphism (736) 736
cytochrome p-450 cyp3a (716) 716
pharmacokinetics (690) 690
liver - enzymology (689) 689
mixed function oxygenases - metabolism (661) 661
genetic aspects (655) 655
enzymes (639) 639
dose-response relationship, drug (617) 617
phenotype (591) 591
molecular sequence data (577) 577
steroid hydroxylases - genetics (576) 576
abridged index medicus (569) 569
cytochrome p-450 cyp2a6 (567) 567
base sequence (563) 563
physiological aspects (560) 560
oncology (557) 557
polymorphism, single nucleotide (552) 552
microsomes, liver - enzymology (551) 551
cyp2c9 (549) 549
oxidoreductases, n-demethylating - genetics (538) 538
aryl hydrocarbon hydroxylases - biosynthesis (531) 531
rna, messenger - metabolism (530) 530
identification (523) 523
induction (516) 516
polymerase chain reaction (513) 513
research (513) 513
cyp2c19 (505) 505
cytochrome p-450 cyp1a1 - genetics (505) 505
genetics & heredity (489) 489
analysis (482) 482
cytochrome p-450 cyp2b6 (482) 482
gene frequency (481) 481
cells, cultured (474) 474
hydroxylation (471) 471
in-vitro (471) 471
warfarin (469) 469
liver (468) 468
cytochrome p-450 enzyme system - biosynthesis (462) 462
kinetics (459) 459
liver - metabolism (458) 458
gene expression (450) 450
liver - drug effects (449) 449
article (445) 445
risk factors (445) 445
cytochrome p450 family 2 (438) 438
human liver-microsomes (431) 431
enzyme induction (422) 422
mutation (418) 418
adolescent (415) 415
genes (415) 415
polymorphisms (401) 401
rna, messenger - genetics (400) 400
aryl-hydrocarbon receptor (393) 393
ticlopidine - analogs & derivatives (392) 392
genetic polymorphisms (391) 391
gene-expression (388) 388
enzyme induction - drug effects (381) 381
drug interactions (380) 380
aged, 80 and over (374) 374
steroid hydroxylases - metabolism (374) 374
cancer (367) 367
vitamin k epoxide reductases (361) 361
oxidoreductases, n-demethylating - metabolism (358) 358
steroid 16-alpha-hydroxylase (358) 358
anticoagulants - administration & dosage (354) 354
warfarin - administration & dosage (351) 351
rats, sprague-dawley (350) 350
association (345) 345
risk (345) 345
receptors, aryl hydrocarbon - metabolism (338) 338
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7656) 7656
Chinese (60) 60
Japanese (59) 59
Russian (54) 54
French (18) 18
German (15) 15
Spanish (13) 13
Polish (9) 9
Swedish (5) 5
Czech (3) 3
Danish (3) 3
Hungarian (3) 3
Dutch (2) 2
Italian (2) 2
Korean (2) 2
Norwegian (2) 2
Romanian (2) 2
Hebrew (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2013, Volume 110, Issue 27, pp. 11115 - 11120
Smoking is a major risk factor for osteoporosis and fracture, but the mechanism through which smoke causes bone loss remains unclear. Here, we show that the... 
Bone resorption | Enzymes | Cell lines | Stem cells | Bones | Osteoclasts | Cultured cells | Bone marrow cells | Cigarette smoking | Aryl hydrocarbon receptors | Osteoblast | Skeletal remodeling | Toxicology | Bone formation | toxicology | TARGET | RESORPTION | MULTIDISCIPLINARY SCIENCES | osteoblast | AHR | skeletal remodeling | CANCER | IN-VITRO | INHIBITION | METABOLISM | bone formation | CIGARETTE-SMOKE | HEALTH | OSTEOCLAST DIFFERENTIATION | Smoking - adverse effects | Cytochrome P-450 CYP1A1 - genetics | Receptors, Aryl Hydrocarbon - deficiency | Aryl Hydrocarbon Hydroxylases - biosynthesis | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Male | Carcinogens - toxicity | Cytochrome P-450 CYP1A2 - genetics | Cytochrome P-450 CYP1A2 - deficiency | Bone Resorption - metabolism | Female | Cytochrome P-450 CYP1A1 - deficiency | Disease Models, Animal | Bone Resorption - etiology | Benzo(a)pyrene - toxicity | Smoke - adverse effects | Mice, Inbred C57BL | Receptors, Aryl Hydrocarbon - genetics | Smoking - genetics | Receptors, Aryl Hydrocarbon - physiology | Tobacco - toxicity | Mice, Knockout | Enzyme Induction - genetics | Animals | Aryl Hydrocarbon Hydroxylases - deficiency | Cytochrome P-450 CYP1A2 - biosynthesis | Bone Resorption - pathology | Cytochrome P-450 CYP1B1 | Polychlorinated Dibenzodioxins - toxicity | Mice | Cytochrome P-450 CYP1A1 - biosynthesis | Osteoporosis | Carcinogens | Cocarcinogens | Hydrocarbons | Physiological aspects | Health aspects | Smoking | Genotype & phenotype | Rodents | Bone marrow | Toxins | Cells | Risk factors | Index Medicus | Biological Sciences
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2009, Volume 360, Issue 4, pp. 354 - 362
The antiplatelet drug clopidogrel requires activation by cytochrome P-450 (CYP) enzymes. This study shows that CYP polymorphisms that reduce clopidogrel... 
MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | STENT THROMBOSIS | HEALTHY-SUBJECTS | INCREASED RISK | PLATELET INHIBITION | ACUTE CORONARY SYNDROMES | PRASUGREL | ST-SEGMENT ELEVATION | INDIVIDUAL RESPONSIVENESS | ATHEROTHROMBOTIC EVENTS | Ticlopidine - pharmacology | Ticlopidine - therapeutic use | Area Under Curve | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Male | Cardiovascular Diseases - genetics | Angioplasty, Balloon, Coronary | Ticlopidine - adverse effects | Ticlopidine - metabolism | Cardiovascular Diseases - epidemiology | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - metabolism | Platelet Aggregation Inhibitors - therapeutic use | Stents | Platelet Aggregation Inhibitors - adverse effects | Genotype | Thrombosis - epidemiology | Combined Modality Therapy | Ticlopidine - analogs & derivatives | Polymorphism, Genetic | Randomized Controlled Trials as Topic | Cytochrome P-450 CYP2C19 | Acute Coronary Syndrome - therapy | Heterozygote | Thrombosis - genetics | Mutation | Usage | Genetic variation | Cytochrome P-450 | Physiological aspects | Causes of | Clopidogrel | Cardiovascular diseases | Health aspects | Risk factors | Studies | Cardiovascular disease | Heart attacks | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 07/2013, Volume 122, Issue 3, pp. 376 - 385
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9894, pp. 790 - 796
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2006, Volume 79, Issue 1, pp. 103 - 113
Background and Objective: Many drugs, including proton pump inhibitors and certain antidepressants, are metabolized by the polymorphic cytochrome P450 (CYP)... 
Mephenytoin - pharmacokinetics | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Male | Ethiopia - epidemiology | Genetic Variation | Transfection | Enzyme Inhibitors - pharmacokinetics | Plasmids - genetics | Electrophoretic Mobility Shift Assay | Anticonvulsants - pharmacokinetics | Omeprazole - therapeutic use | Proton Pump Inhibitors | Gene Frequency | Genes, Reporter - genetics | Genotype | Omeprazole - pharmacokinetics | China - epidemiology | Reverse Transcriptase Polymerase Chain Reaction | Sweden - epidemiology | Enzyme Inhibitors - therapeutic use | Antidepressive Agents - therapeutic use | Phenotype | Animals | Cytochrome P-450 CYP2C19 | Mice | Mutation | Antidepressive Agents - pharmacokinetics | Mixed Function Oxygenases - genetics | Physiological aspects | Genetic research | Proton pump inhibitors | Cytochrome P-450 | Antidepressants, Tricyclic | Index Medicus | Abridged Index Medicus | Plasmids/genetics | Omeprazole/pharmacokinetics/therapeutic use | Antidepressive Agents/pharmacokinetics/therapeutic use | Ethiopia/epidemiology | Proton Pumps/antagonists & inhibitors | Mephenytoin/pharmacokinetics | Enzyme Inhibitors/pharmacokinetics/therapeutic use | China/epidemiology | Genes; Reporter/genetics | Mixed Function Oxygenases/genetics | Anticonvulsants/pharmacokinetics | Variation (Genetics) | Aryl Hydrocarbon Hydroxylases/genetics | Sweden/epidemiology
Journal Article
Circulation, ISSN 0009-7322, 08/2012, Volume 126, Issue 9, pp. 1087 - 1098
Background-Pulmonary arterial hypertension (PAH) is a hyperproliferative vascular disorder observed predominantly in women. Estrogen is a potent mitogen in... 
Hypertension | Animal | Estrogens | Models | Cardiovascular diseases | Metabolism | Pulmonary | models animal | SEROTONIN TRANSPORTER | CARDIAC & CARDIOVASCULAR SYSTEMS | hypertension pulmonary | P450CYP1B1 | estrogens | cardiovascular diseases | P4501B1 CYP1B1 | HYPOXIA | BREAST-CANCER | IN-VIVO | ESTRADIOL | GENE-EXPRESSION | PERIPHERAL VASCULAR DISEASE | metabolism | MICE | 2-METHOXYESTRADIOL | Up-Regulation | Aryl Hydrocarbon Hydroxylases - biosynthesis | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Myocytes, Smooth Muscle - pathology | Male | Stilbenes - pharmacology | Hypertension, Pulmonary - chemically induced | Lung - enzymology | Cell Hypoxia | Hydroxyestrones - toxicity | Aryl Hydrocarbon Hydroxylases - physiology | Female | Estrogens - metabolism | Myocytes, Smooth Muscle - metabolism | Estradiol - pharmacology | Hypertension, Pulmonary - enzymology | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cells, Cultured - drug effects | Lung - pathology | Hydroxyestrones - pharmacology | Enzyme Induction | Hypoxia - complications | Hypertrophy, Right Ventricular - enzymology | Reverse Transcriptase Polymerase Chain Reaction | Pulmonary Artery - enzymology | Mice, Knockout | Animals | Aryl Hydrocarbon Hydroxylases - deficiency | Hydroxyestrones - metabolism | Cytochrome P-450 CYP1B1 | Cells, Cultured - metabolism | Mice | Chronic Disease | Hypertension, Pulmonary - etiology | Hypertension, Pulmonary - pathology | Pulmonary Artery - pathology | Physiological aspects | Development and progression | Research | Pulmonary hypertension | Cytochrome P-450 | Estrogen | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9749, pp. 1312 - 1319
Summary Background Clopidogrel and prasugrel are subject to efflux via P-glycoprotein (encoded by ABCB1 , also known as MDR1 ). ABCB1 polymorphisms,... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEALTHY JAPANESE SUBJECTS | RESPONSIVENESS | STENT THROMBOSIS | DUODENAL ENTEROCYTES | OF-FUNCTION POLYMORPHISM | PLATELET INHIBITION | MDR1 GENE | EXPRESSION | P-GLYCOPROTEIN | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Thiophenes - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Male | Angioplasty, Balloon, Coronary | Genetic Variation | Ticlopidine - adverse effects | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Pharmacogenetics | Genotype | Piperazines - therapeutic use | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Randomized Controlled Trials as Topic | Acute Coronary Syndrome - drug therapy | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Cytochrome P-450 CYP2C19 | ATP Binding Cassette Transporter, Sub-Family B | Polymorphism, Single Nucleotide | Acute Coronary Syndrome - genetics | Physiological aspects | Clopidogrel | Dosage and administration | Cardiovascular diseases | Drug therapy | Patient outcomes | Studies | Fees & charges | Heart attacks | Stock options | Acute coronary syndromes | Mass spectrometry | Drugs | Pharmacodynamics | Clinical trials | P-Glycoprotein | Pharmacokinetics | Index Medicus | Abridged Index Medicus
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 1, pp. 16 - 22.e1
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9827, pp. 1705 - 1711
Journal Article